SEARCH

SEARCH BY CITATION

References

  • 1
    Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004; 7: 1928.
  • 2
    Pimentel M, Chow EJ, Lin HC. Normalization lactulose breath test correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 3
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 35036.
    Direct Link:
  • 4
    Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 115760.
  • 5
    Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol 2002; 97: 111326.
    Direct Link:
  • 6
    Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95: 9828.
  • 7
    Kerlin P. Glucose-H2 breath test for small intestinal bacterial overgrowth. Gastroenterology 1990; 98: 2534.
  • 8
    Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 3029.
  • 9
    Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73(Suppl. 1): 1327.
  • 10
    Corazza GR, Di Stefano M, Scarpignato C. Treatment of functional bowel disorders: is there room for antibiotics? Digestion 2006; 73(Suppl. 1): 3846.
  • 11
    DuPont HL. New insights and directions in travelers’ diarrhea. Gastroenterol Clin North Am 2006; 35: 33753.
  • 12
    DuPont HL. Travellers’ diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006; 66: 30314.
  • 13
    Pelosini I, Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy 2005; 51(Suppl. 1): 12230.
  • 14
    DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005; 142: 80512.
  • 15
    Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 315.
  • 16
    Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122: 170114.
  • 17
    Corazza GR, Benati G, Strocchi A, et al. The possible role of breath methane measurement in detecting carbohydrate malabsorption. J Lab Clin Med 1994; 124: 695700.
  • 18
    Van Citters GW, Lin HC. Management of small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2005; 7: 31720.
  • 19
    Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005; 5: 1930.
  • 20
    Di Stefano M, Miceli E, Missanelli A, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 5516.
  • 21
    Tursi A, Brandimarte G, Giorgetti GM, et al. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005; 11: 27736.
  • 22
    Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006; 52: 8995.